Drugs of today最新文献

Current status of treatment for chronic hepatitis C virus infection. 慢性丙型肝炎病毒感染的治疗现状

IF 1.8 4区医学

Drugs of today Pub Date : 2012-03-01 DOI: 10.1358/dot.2012.48.3.1740457

R Talwani, B L Gilliam, S A Rizza, V Nehra, Z Temesgen

引用次数: 11

A report from the 27th Annual Congress Of The European Association Of Urology (February 24-28, 2012 - Paris, France). 来自第27届欧洲泌尿外科协会年会上(2012年2月24-28日，法国巴黎)的一份报告。

IF 1.8 4区医学

Drugs of today Pub Date : 2012-03-01 DOI: 10.1358/dot.2012.48.3.1790306

X Rabasseda

引用次数: 0

Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. 重新审视可乐定:一种治疗注意力缺陷/多动障碍的创新附加选择。

IF 1.8 4区医学

Drugs of today Pub Date : 2012-03-01 DOI: 10.1358/dot.2012.48.3.1750904

A C Childress, F R Sallee

{"title":"Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder.","authors":"A C Childress, F R Sallee","doi":"10.1358/dot.2012.48.3.1750904","DOIUrl":"https://doi.org/10.1358/dot.2012.48.3.1750904","url":null,"abstract":"Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder characterized by developmentally inappropriate levels of inattention, hyperactivity and impulsivity. Although much evidence supports the use of psychostimulants as a first-line treatment in children and adolescents, up to 30% of patients may have an inadequate response to these medications. For these patients, addition of an α₂-adrenoceptor agonist can further improve ADHD symptoms. The α₂-adrenoceptor agonists may work in a synergistic fashion with stimulants through regulation of prefrontal cortex function. Early studies were completed with immediate-release clonidine (CLON-IR), which requires multiple daily doses and achieves a higher maximum concentration more rapidly than the more recently developed extended-release clonidine (CLON-XR). Pharmacokinetic properties of CLON-XR may be responsible for differences in efficacy and tolerability between the CLON-IR and CLON-XR formulations. Recent double-blind, placebo-controlled trials have shown that extended-release α₂-adrenoceptor agonists are safe and effective, both as monotherapy and as adjunctive treatment with stimulants. This review will focus on clonidine used in conjunction with stimulants to optimize treatment of ADHD.","PeriodicalId":11397,"journal":{"name":"Drugs of today","volume":" ","pages":"207-17"},"PeriodicalIF":1.8,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30541232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Eldecalcitol for the treatment of osteoporosis. 依地骨糖醇治疗骨质疏松症。

IF 1.8 4区医学

Drugs of today Pub Date : 2012-03-01 DOI: 10.1358/dot.2012.48.3.1745223

T Matsumoto, I Endo

引用次数: 10

Linaclotide in the management of gastrointestinal tract disorders. 利那洛肽在胃肠道疾病治疗中的应用。

IF 1.8 4区医学

Drugs of today Pub Date : 2012-03-01 DOI: 10.1358/dot.2012.48.3.1745228

B E Lacy, J M Levenick, M D Crowell

{"title":"Linaclotide in the management of gastrointestinal tract disorders.","authors":"B E Lacy, J M Levenick, M D Crowell","doi":"10.1358/dot.2012.48.3.1745228","DOIUrl":"https://doi.org/10.1358/dot.2012.48.3.1745228","url":null,"abstract":"Chronic constipation is a highly prevalent, heterogeneous disorder that significantly affects patients' lives. Nearly 15% of the U.S. population meets diagnostic criteria for chronic constipation (1). Chronic constipation reduces patients' quality of life and imposes a significant economic burden to the healthcare system (2, 3). A number of therapeutic options are currently available to treat symptoms of chronic constipation, although they are not universally successful (4, 5). Irritable bowel syndrome (IBS) is another common functional gastrointestinal disorder, with a prevalence rate estimated at up to 12% in the U.S. (6). Similar to chronic constipation, IBS imposes a significant impact on both the healthcare system and the individual patient (7-12). Currently, only one medication (lubiprostone) is approved by the U.S. Food and Drug Administration for the treatment of IBS with constipation (IBS-C), and is approved only for women (13). Although effective in many patients, it is not universally effective for the treatment of constipation symptoms in all patients with IBS-C. Other treatment options are therefore needed for those patients with chronic constipation and IBS-C who fail currently available therapies. This article will present information on the pharmacology and pharmacokinetics of linaclotide, a new agent designed to treat symptoms of both chronic constipation and IBS-C. Preclinical data, clinical studies and safety data will also be reviewed.","PeriodicalId":11397,"journal":{"name":"Drugs of today","volume":" ","pages":"197-206"},"PeriodicalIF":1.8,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30541231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Lurasidone: a new treatment option for schizophrenia. 鲁拉西酮:精神分裂症的新治疗选择。

IF 1.8 4区医学

Drugs of today Pub Date : 2011-11-01 DOI: 10.1358/dot.2011.47.11.1708832

R T Owen

{"title":"Lurasidone: a new treatment option for schizophrenia.","authors":"R T Owen","doi":"10.1358/dot.2011.47.11.1708832","DOIUrl":"https://doi.org/10.1358/dot.2011.47.11.1708832","url":null,"abstract":"Lurasidone is a novel benzoisothiazol antipsychotic that has recently been approved for the treatment of schizophrenia in the U.S. Like many other second-generation antipsychotics, it has a high affinity for dopamine D(2) and serotonin 5-HT(2A) receptors as well as a high affinity for 5-HT(7) receptors. It has negligible affinity for α(1)-adrenoceptors, histamine H(1) receptors or muscarinic acetylcholine M(1) receptors. It has demonstrated efficacy in short-term trials versus placebo, two of which included an active comparator (olanzapine, quetiapine) assay arm. A short-term, head-to-head trial of lurasidone versus ziprasidone in chronic stable schizophrenia was also conducted. A long-term, 12-month risperidone-controlled study and open-label studies primarily investigated the safety and tolerability of lurasidone. Limited evidence of procognitive and antidepressant effects was seen although these need further corroboration. The incidence of extrapyramidal symptoms (excluding akathisia/restlessness) was greater with lurasidone (14.7%) than placebo (5.1%). Akathisia and somnolence were dose-related adverse events. Lurasidone appears to have relatively little effect on weight, plasma glucose or lipids to date. No evidence of QTc prolongation was seen and orthostatic hypotension was uncommon. Raised prolactin levels in short-term studies were dose-dependent, greater in females and occurred overall in 3.7 and 0.7% of lurasidone and placebo recipients, respectively.","PeriodicalId":11397,"journal":{"name":"Drugs of today","volume":" ","pages":"807-16"},"PeriodicalIF":1.8,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30306186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). 临床开发多靶点酪氨酸激酶抑制剂:重点是XL-184 (cabozantinib)。

IF 1.8 4区医学

Drugs of today Pub Date : 2011-11-01 DOI: 10.1358/dot.2011.47.11.1688487

D W Bowles, E R Kessler, A Jimeno

引用次数: 33

An update on exenatide, a novel therapeutic option for patients with type 2 diabetes. 艾塞那肽的最新进展，一种治疗2型糖尿病患者的新选择。

IF 1.8 4区医学

Drugs of today Pub Date : 2011-11-01 DOI: 10.1358/dot.2011.47.11.1688575

W Crasto, K Khunti, M J Davies

{"title":"An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.","authors":"W Crasto, K Khunti, M J Davies","doi":"10.1358/dot.2011.47.11.1688575","DOIUrl":"https://doi.org/10.1358/dot.2011.47.11.1688575","url":null,"abstract":"Exenatide, a synthetic glucagon GLP-1 receptor agonist, belongs to a new class of agents approved as a treatment option in patients with poorly controlled type 2 diabetes not adequately controlled on oral antidiabetic agents. The principal mode of drug action includes enhanced glucose-dependent insulin secretion --the so called \"incretin effect\"-- suppression of glucagon and inhibition of endogenous glucose production. The potential to address these dysregulated pathways allows exenatide to be a valuable adjunct to existing treatment options for patients with poorly controlled type 2 diabetes. Clinical trials with twice-daily exenatide have shown significant improvements in glycemic control (HbA(1c) reductions of 0.8-1% across studies), progressive weight loss and low incidence of hypoglycemia. Common side effects include nausea and vomiting which usually subside after a few days of therapy and do not usually necessitate withdrawal of the drug. In recent months, a longer-acting, once-weekly preparation of exenatide, which is currently approved for use in Europe, has shown promise and phase III studies indicate that it may be more potent and efficacious than existing twice-daily preparations. Meanwhile, the results from long-term studies to assess cardiovascular benefits with exenatide therapy are eagerly awaited.","PeriodicalId":11397,"journal":{"name":"Drugs of today","volume":" ","pages":"839-56"},"PeriodicalIF":1.8,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30306102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

A report from the 2011 Alzheimer's Association International Conference (July 16-21 - Paris, France). 一份来自2011年阿尔茨海默病协会国际会议(7月16-21日，法国巴黎)的报告。

IF 1.8 4区医学

Drugs of today Pub Date : 2011-11-01 DOI: 10.1358/dot.2011.47.11.1727784

X Rabasseda, C Dulsat

引用次数: 0

Telaprevir: looking for a sustained virologic response in hepatitis C virus infection. 替拉韦:寻找丙型肝炎病毒感染的持续病毒学反应。

IF 1.8 4区医学

Drugs of today Pub Date : 2011-11-01 DOI: 10.1358/dot.2011.47.11.1678339

V Nehra, S A Rizza, R Talwani, Z Temesgen

引用次数: 0